BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Global Biodefense - ECPv6.18.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://globalbiodefense.com
X-WR-CALDESC:Events for Global Biodefense
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220614T083000
DTEND;TZID=America/New_York:20220614T170000
DTSTAMP:20220527T205853Z
CREATED:20220527T205356Z
LAST-MODIFIED:20220527T205853Z
UID:55113-1655195400-1655226000@globalbiodefense.com
SUMMARY:VRBPAC Meeting to Review Moderna Pediatric (Ages 6-17) mRNA Vaccine EAU
DESCRIPTION:The VRBPAC committee will meet in open session on June 14\, 2022 to discuss amending the EUA of the Moderna COVID-19 mRNA vaccine to include the administration of the primary series to children and adolescents 6 years through 17 years of age. \nFDA intends to make background material available to the public no later than 2 business days before the meeting.  If FDA is unable to post the background material on its website prior to the meeting\, any background material will be made publicly available at the time of the advisory committee meeting\, and additional materials will be posted on FDA’s website after the meeting. \nMaterials for this meeting will be available at the Vaccines and Related Biological Products Advisory Committee meetings main page. \nInterested persons may present data\, information\, or views\, orally or in writing\, on issues pending before the committee. FDA is establishing a docket for public comment on this meeting. The Docket Number is FDA-2022-N-0904 \nOn June 15\, 2022\, under Topic II\, the committee will meet in open session to discuss amending the EUA of the Moderna COVID-19 mRNA vaccine to include the administration of the primary series to infants and children 6 months through 5 years of age\, and also to discuss amending the EUA of the Pfizer-BioNTech COVID-19 mRNA vaccine to include the administration of the primary series to infants and children 6 months through 4 years of age. \n  \n  \n 
URL:https://globalbiodefense.com/event/vrbpac-meeting-to-review-moderna-pediatric-ages-6-17-mrna-vaccine-eau/
CATEGORIES:Government Hosted,Webinar-Webcast
LOCATION:https://www.youtube.com/watch?v=GbNpaZeDPiA
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220615T083000
DTEND;TZID=America/New_York:20220615T170000
DTSTAMP:20220527T210409Z
CREATED:20220527T210409Z
LAST-MODIFIED:20220527T210409Z
UID:55115-1655281800-1655312400@globalbiodefense.com
SUMMARY:VRBPAC Meeting to Review Pediatric (Infant - 5 Years) mRNA Vaccines
DESCRIPTION:The VRBPAC will meet in open session to discuss amending the EUA of the Moderna COVID-19 mRNA vaccine to include the administration of the primary series to infants and children 6 months through 5 years of age\, and also to discuss amending the EUA of the Pfizer-BioNTech COVID-19 mRNA vaccine to include the administration of the primary series to infants and children 6 months through 4 years of age. \nFDA intends to make background material available to the public no later than 2 business days before the meeting.  If FDA is unable to post the background material on its website prior to the meeting\, any background material will be made publicly available at the time of the advisory committee meeting\, and additional materials will be posted on FDA’s website after the meeting. \nMaterials for this meeting will be available at the Vaccines and Related Biological Products Advisory Committee meetings main page. \nInterested persons may present data\, information\, or views\, orally or in writing\, on issues pending before the committee. FDA is establishing a docket for public comment on this meeting. The Docket Number is FDA-2022-N-0904.
URL:https://globalbiodefense.com/event/vrbpac-meeting-to-review-pediatric-infant-5-years-mrna-vaccines/
CATEGORIES:Government Hosted,Webinar-Webcast
LOCATION:https://www.youtube.com/watch?v=Ixm4UmldTGQ
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220628T083000
DTEND;TZID=America/New_York:20220628T170000
DTSTAMP:20220527T213139Z
CREATED:20220527T213139Z
LAST-MODIFIED:20220527T213139Z
UID:55118-1656405000-1656435600@globalbiodefense.com
SUMMARY:VRBPAC Meeting on COVID-19 Vaccine Strain Composition Decisions
DESCRIPTION:The VRBPAC will meet in open session on 28 June 2022 to discuss whether and how the SARS-CoV-2 strain composition of COVID-19 vaccines should be modified. \nFDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting\, any background material will be made publicly available at the time of the advisory committee meeting\, and additional materials will be posted on FDA’s website after the meeting. \nMaterials for this meeting will be available at the Vaccines and Related Biological Products Advisory Committee meetings main page. \nInterested persons may present data\, information\, or views\, orally or in writing\, on issues pending before the committee. FDA is establishing a docket for public comment on this meeting. \nThe Docket Number is FDA-2022-N-0905
URL:https://globalbiodefense.com/event/vrbpac-meeting-on-covid-19-vaccine-strain-composition-decisions/
CATEGORIES:Government Hosted,Webinar-Webcast
LOCATION:https://www.youtube.com/watch?v=BFdzNUus_CE
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220629T120000
DTEND;TZID=America/New_York:20220629T170000
DTSTAMP:20220622T153805Z
CREATED:20220622T153805Z
LAST-MODIFIED:20220622T153805Z
UID:55703-1656504000-1656522000@globalbiodefense.com
SUMMARY:USG Policies for the Oversight of Life Sciences Dual Use Research of Concern
DESCRIPTION:The purpose of this meeting is to gather feedback from stakeholders about their experiences implementing these policies\, the effect of these policies in terms of achieving their stated goals\, the overarching definition of DURC\, and possible alternative approaches for the oversight and responsible conduct of DURC. \nThis feedback will also be used to inform the discussions of the National Science Advisory Board for Biosecurity (NSABB) in fulfillment their current charge to evaluate and analyze the DURC policies. \nRegistration is not required to view the webcast. \nREAD MORE: Dual Use Research of Concern: NIH to Host Stakeholder Engagement Meeting on Oversight Policies
URL:https://globalbiodefense.com/event/usg-policies-for-the-oversight-of-life-sciences-dual-use-research-of-concern/
CATEGORIES:Conference,Government Hosted
LOCATION:https://osp.od.nih.gov/event/virtual-stakeholder-engagement-meeting-on-usg-policies/
END:VEVENT
END:VCALENDAR